EVIIVE AG

Our startup specializes in the cutting-edge field of extracellular vesicle (EV) biomarker discovery, utilizing single EV analysis and machine learning to revolutionize precision medicine. We provide a novel platform that significantly enhances the sensitivity and specificity of biomarker identification and allows healthcare professionals to diagnose conditions at an early stage, facilitating timely and personalized treatment options. We are committed to improving patient outcomes by bridging critical gaps in current diagnostic biomarkers. Our approach holds the potential to transform therapeutic strategies across a spectrum of diseases. With a focus on innovation and a strong IP strategy, we aim to lead the market in delivering robust and data-driven solutions for biomarker discovery.